Hepatocellular Carcinoma Antibody (CHALV1): sc-52860

Hepatocellular Carcinoma Antibody (CHALV1) is a mouse monoclonal IgG1 kappa light chain antibody that detects the Hepatocellular Carcinoma protein of human origin by enzyme-linked immunosorbent assay (ELISA). Anti-Hepatocellular Carcinoma antibody (CHALV1) is available as the non-conjugated form. Hepatocellular carcinoma (HCC) is a malignancy that originates from hepatocytes, the primary functional cells of the liver, and is responsible for 80-90% of all liver cancer cases, with a higher incidence in men compared to women. This aggressive cancer is a leading cause of cancer-related mortality globally, often linked to risk factors such as cirrhosis, hepatitis B and C infections, and exposure to aflatoxins. Hepatocellular Carcinoma protein plays a crucial role in tumor progression and metastasis, making Hepatocellular Carcinoma protein a significant target for therapeutic intervention and biomarker development. Understanding the interactions of Hepatocellular Carcinoma protein with specific signaling pathways can provide insights into the mechanisms of HCC development and progression, ultimately aiding in the identification of potential treatment strategies. Symptoms of HCC include abdominal pain, an enlarged abdomen, easy bruising, and jaundice, highlighting the importance of early detection and monitoring.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Hepatocellular Carcinoma Antibody (CHALV1) References:

1. Expression of P-glycoprotein and C-MOAT in human hepatocellular carcinoma: detection by immunostaining.  |  Richart, J., et al. 2002. Dig Dis Sci. 47: 2454-8. PMID: 12452378
2. Role of injury and hyperplasia in the induction of hepatocellular carcinoma.  |  GOLDFARB, S. and ZAK, FG. 1961. JAMA. 178: 729-31. PMID: 13899750
3. [A case of hepatocellular carcinoma of the liver with diffuse metastases in the spleen].  |  BEHRENS, H. 1951. Zentralbl Allg Pathol. 87: 18-23. PMID: 14828929
4. Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: Detection of generated fragments in patient sera.  |  Chignard, N., et al. 2006. Gastroenterology. 130: 2010-22. PMID: 16762624
5. [Clinical evaluation of PIVKA-II in patients with hepatocellular carcinoma. Detection of PIVKA-II by EIA using anti-PIVKA-II monoclonal antibody].  |  Ohtani, M., et al. 1989. Rinsho Byori. 37: 405-9. PMID: 2545953
6. Hepatocellular carcinoma in association with a specific fetal alpha-1-globulin, fetoprotein.  |  Houstĕk, J., et al. 1968. J Pediatr. 72: 186-93. PMID: 4169729
7. Viral hepatitis, postnecrotic cirrhosis, and hepatocellular carcinoma.  |  Smith, JB. and Blumberg, BS. 1969. Lancet. 2: 953. PMID: 4186610
8. The alpha 1-fetoprotein test in hepatocellular carcinoma.  |  Fox, H., et al. 1970. Lancet. 1: 411. PMID: 4189706
9. Immunofluorescent localisation of human alpha feto-protein in fetal and neonatal livers and cultured cells from hepatocellular carcinoma.  |  Smith, JA., et al. 1971. Br J Cancer. 25: 343-9. PMID: 4329952